Brief: Alzamend Neuro Announces Full Data Set From Phase 1 First-In-Human Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer's

Alzamend Neuro

28/03/2022 13:58

March 28 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM PHASE 1
FIRST-IN-HUMAN CLINICAL TRIAL FOR AL001 TREATMENT OF DEMENTIA
RELATED TO ALZHEIMER'S
    * ALZAMEND NEURO INC - RESULTS SHOW THAT SHAPES OF LITHIUM
PLASMA
CONCENTRATION VERSUS TIME CURVES ARE SIMILAR TO MARKETED PRODUCT
    * ALZAMEND NEURO INC - AL001 SALICYLATE PLASMA
CONCENTRATIONS WERE
OBSERVED TO BE WELL TOLERATED AND CONSISTENTLY WITHIN SAFE
LIMITS
    * ALZAMEND NEURO INC - SAFETY PROFILES OF BOTH AL001 AND
MARKETED
LITHIUM CARBONATE CAPSULE WERE BENIGN
    * ALZAMEND NEURO INC - LOOK FORWARD TO INITIATING A PHASE 2
MULTIPLE ASCENDING DOSE STUDY INVOLVING ALZHEIMER'S PATIENTS IN
Q2 OF 2022
    * ALZAMEND NEURO INC - LOOK FORWARD TO PURSUING IND
APPLICATIONS
WITH U.S. FDA DURING 2022 FOR BIPOLAR DISORDER, DEPRESSION, AND
PTSD INDICATIONS

Source text for Eikon:  ID:nBw5n2Ybla 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))